Literature DB >> 8142468

Human alpha-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6.

S Ishii1, R Kase, H Sakuraba, S Fujita, M Sugimoto, K Tomita, T Semba, Y Suzuki.   

Abstract

Two proteins with alpha-galactosidase activity, alpha-galactosidase A (alpha-GalA) and alpha-galactosidase B (alpha-GalB, or alpha-N-acetylgalactosaminidase; alpha-NAGA) have a high homology of amino-acid sequence. Point mutations of the alpha-GalA gene have been reported only in the exons 1, 2 or 6. In this study, the exon 1-2 and/or 6 sequences of alpha-GalA cDNA were partly substituted by the corresponding regions of alpha-GalB cDNA, and three chimeric proteins were prepared by the baculovirus expression system: CMB12 with substitution at the exon 1-2 region, CMB6 at the exon 6 region, and CMB126 at both regions. They all preserved alpha-GalA antigenicity. Their kinetic properties toward 4-methylumbelliferyl alpha-galactopyranoside were compared with those of alpha-GalA. The catalytic activity was slightly low in CMB12, decreased to 1/10 in CMB6, and restored to a significant degree in CMB126. Km was more than 4-fold higher for CMB6 and CMB126 than for alpha-GalA. The pH optimum was 4.0 for both CMB12 and alpha-GalA, 4.8 for CMB6, and 4.6 for CMB126 and alpha-GalB. The catalytic activity was inhibited most by galactosamine in CMB6, and less in alpha-GalB, CMB126, alpha-GalA and CMB12 in decreasing order. The 50% inhibition concentrations of melibiose (Gal alpha 1-6Glc) and methyl alpha-galactopyranoside were 2.5- to 3-fold higher for CMB126 than for alpha-GalA. These results indicate that the low affinity of CMB126 to the substrate was caused by a reduced affinity to terminal alpha-linked galactose. We conclude that (1) the two regions encoded by exons 1-2 and 6 contribute to the alpha-galactosidic cleavage, and (2) an increase in Km of CMB6 or CMB126, with chimeric substitutions at the exon 6 region, was caused by a loss of affinity toward terminal alpha-linked galactose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142468     DOI: 10.1016/0167-4838(94)90017-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.

Authors:  Hitoshi Sakuraba; Mai Murata-Ohsawa; Ikuo Kawashima; Youichi Tajima; Masaharu Kotani; Toshio Ohshima; Yasunori Chiba; Minako Takashiba; Yoshifumi Jigami; Tomoko Fukushige; Tamotsu Kanzaki; Kohji Itoh
Journal:  J Hum Genet       Date:  2005-12-22       Impact factor: 3.172

2.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

3.  The DAG family of glycosyl hydrolases combines two previously identified protein families.

Authors:  B H Dagnall; I T Paulsen; M H Saier
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

4.  Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins.

Authors:  T Okumiya; S Ishii; R Kase; S Kamei; H Sakuraba; Y Suzuki
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

5.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

6.  Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery.

Authors:  Hitoshi Sakuraba; Yasunori Chiba; Masaharu Kotani; Ikuo Kawashima; Mai Ohsawa; Youichi Tajima; Yuki Takaoka; Yoshifumi Jigami; Hiroshi Takahashi; Yukihiko Hirai; Takashi Shimada; Yasuhiro Hashimoto; Kumiko Ishii; Toshihide Kobayashi; Kazuhiko Watabe; Tomoko Fukushige; Tamotsu Kanzaki
Journal:  J Hum Genet       Date:  2006-03-11       Impact factor: 3.172

7.  Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues.

Authors:  S Ishii; R Kase; H Sakuraba; C Taya; H Yonekawa; T Okumiya; Y Matsuda; K Mannen; M Takeshita; Y Suzuki
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

8.  Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice.

Authors:  Gen Nakamura; Hiroki Maruyama; Satoshi Ishii; Masaaki Shimotori; Shigemi Kameda; Toru Kono; Jun-ichi Miyazaki; Ashok B Kulkarni; Fumitake Gejyo
Journal:  Mol Biotechnol       Date:  2007-10-13       Impact factor: 2.695

9.  Pharmacological chaperone therapy for Fabry disease.

Authors:  Satoshi Ishii
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

10.  Development of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase A protein levels in serum and plasma.

Authors:  Sachie Nakano; Yoshihito Morizane; Noriko Makisaka; Toshihiro Suzuki; Tadayasu Togawa; Takahiro Tsukimura; Ikuo Kawashima; Hitoshi Sakuraba; Futoshi Shibasaki
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.